866-997-4948(US-Canada Toll Free)

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Published By :

Transparency Market Research

Published Date : Apr 2018

Category :

In Vitro Diagnostics

No. of Pages : 176 Pages

Global Scleroderma Diagnostics and Therapeutics Market: Overview

The scleroderma diagnostics and therapeutics market report studies the scleroderma diagnostics and therapeutics market globally as well as regionally for the forecast period from 2017 to 2024. The report provides valuable insights into the growth of the said market, wherein revenue estimates are presented in US$ Mn and volume estimates in Kilo tons.

Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various scleroderma drugs as well as new entrants planning to enter this market.

Included in the study is a detailed discussion on vital market indicators, which include demand drivers, challenges, and opportunities. The impact of these indicators on the scleroderma diagnostics and therapeutics market over the aforementioned forecast period have been ascertained as well. Furthermore, the report also examines growth trends and technological advancements that are likely to have a bearing on the growth of scleroderma diagnostics and therapeutics market between 2017 and 2024.

Following this, the report discusses value chain analysis to throw light on demand supply dynamics in the scleroderma diagnostics and therapeutics market. Industry-centric analytical tools such as SWOT analysis and Porter’s five forces have been employed for insights into the competitive landscape of the scleroderma diagnostics and therapeutics market. In addition, the report presents market attractiveness analysis wherein key segments within drug class, indication, test type, and geography have been identified and analyzed for their growth behavior.

Global Scleroderma Diagnostics and Therapeutics Market: Research Methodology

The report has been prepared after an elaborate primary and secondary research phase. Thus, the analysis of the scleroderma diagnostics and therapeutics market presented in reliable to a high degree. The primary research phase involved carrying out telephonic as well face-to-face interviews with industry experts along with e-mail interactions. Primary research represent major part of research efforts along with a secondary research phase. Industry stakeholders who participated in the primary research phase include CEOs, VPs, market intelligence managers, marketing/product managers, and national sales managers. Purchasing managers, technical experts, suppliers and traders were some other stakeholders who were reached out in the primary research phase. Rheumatologists, dermatologists, and physicians treating scleroderma patients were also reached out in the primary research phase of the making of the report.

Secondary research phase involved reaching out to industry-centric databases for data collection followed by data scrutiny. Secondary sources reached out include key players’ product literature, annual reports, relevant business documents, and trade journals. Some other secondary sources reached out include trade journals, technical writings, government websites, trade associations, Internet sources, and online paid databases.

Secondary research sources reached out for the study include stock analyst websites, company website sources, governmental organizations and public portals, Orange Book – FDA, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Clinicaltrials.gov, Clinicaltrialsregister.eu, journals and other publications.

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014–2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials

Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication 
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Localized
5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments

Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Endothelin receptor antagonists 
6.3.4. Calcium Channel Blockers
6.3.5. PDE-5 Inhibitors
6.3.6. Chelating Agents
6.3.7. Prostacyclin analogues
6.3.8. Others 
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments

Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends

Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication 
8.3.1. Localized
8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
8.4.1. Corticosteroids
8.4.2. Immunosuppressive Agents
8.4.3. Endothelin receptor antagonists 
8.4.4. Calcium Channel Blockers
8.4.5. PDE-5 Inhibitors
8.4.6. Chelating Agents
8.4.7. Prostacyclin analogues
8.4.8. Others 
8.5. Market Size (US$ Mn) Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends

Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
9.3.1. Localized
9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
9.4.1. Corticosteroids
9.4.2. Immunosuppressive Agents
9.4.3. Endothelin receptor antagonists 
9.4.4. Calcium Channel Blockers
9.4.5. PDE-5 Inhibitors
9.4.6. Chelating Agents
9.4.7. Prostacyclin analogues
9.4.8. Others 
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.K.
9.5.2. Germany
9.5.3. France
9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015 
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends

Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
10.3.1. Localized
10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
10.4.1. Corticosteroids
10.4.2. Immunosuppressive Agents
10.4.3. Endothelin receptor antagonists 
10.4.4. Calcium Channel Blockers
10.4.5. PDE-5 Inhibitors
10.4.6. Chelating Agents
10.4.7. Prostacyclin analogues
10.4.8. Others 
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. China
10.5.2. India
10.5.3. Japan
10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2015 
10.7. Market Attractiveness Analysis, by Drug Class, 2015
10.8. Key Trends

Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product 
11.3.1. Localized
11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
11.4.1. Corticosteroids
11.4.2. Immunosuppressive Agents
11.4.3. Endothelin receptor antagonists 
11.4.4. Calcium Channel Blockers
11.4.5. PDE-5 Inhibitors
11.4.6. Chelating Agents
11.4.7. Prostacyclin analogues
11.4.8. Others 
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2015 
11.7. Market Attractiveness Analysis, by Drug Class, 2015
11.8. Key Trends

Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication 
12.3.1. Localized
12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
12.4.1. Corticosteroids
2.4.2. Immunosuppressive Agents
12.4.3. Endothelin receptor antagonists 
12.4.4. Calcium Channel Blockers
12.4.5. PDE-5 Inhibitors
12.4.6. Chelating Agents
12.4.7. Prostacyclin analogues
12.4.8. Others 
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. UAE
12.5.2. South Africa
12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2015 
12.7. Market Attractiveness Analysis, by Drug Class, 2015
12.8. Key Trends

Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
13.2.1. Actelion Pharmaceuticals, Inc. 
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Financial Overview
13.2.1.3. Product Portfolio
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Bayer AG
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Financial Overview
13.2.2.3. Product Portfolio
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. Boehringer Ingelheim
13.2.3.1. Company Overview (HQ, business segments, employee strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Corbus Pharmaceutical Holdings, Inc. 
13.2.4.1. Company Overview (HQ, business segments, employee strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Strategic Overview
13.2.4.5. Key Developments
13.2.5. Cumberland Pharmaceuticals Inc.
13.2.5.1. Company Overview (HQ, business segments, employee strength)
13.2.5.2. Financial Overview
13.2.5.3. Product Portfolio
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. Cytori Therapeutics, Inc.
13.2.6.1. Company Overview (HQ, business segments, employee strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. F. Hoffmann La Roche Ltd. 
13.2.7.1. Company Overview (HQ, business segments, employee strength)
13.2.7.2. Financial Overview
13.2.7.3. Product Portfolio
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. Gilead Sciences, Inc. 
13.2.8.1. Company Overview (HQ, business segments, employee strength)
13.2.8.2. Financial Overview
13.2.8.3. Product Portfolio
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Merck KGaA
13.2.9.1. Company Overview (HQ, business segments, employee strength)
13.2.9.2. Product Portfolio
13.2.9.3. Financial Overview
13.2.9.4.SWOT Analysis
13.2.9.5. Strategic Overview
13.2.10. Pfizer, Inc.
13.2.10.1. Company Overview (HQ, business segments, employee strength)
13.2.10.2. Product Portfolio
13.2.10.3. Financial Overview
13.2.10.4. SWOT Analysis
13.2.10.5. Strategic Overview
13.2.11. Sanofi
13.2.11.1. Company Overview (HQ, business segments, employee strength)
13.2.11.2. Product Portfolio
13.2.11.3. Financial Overview
13.2.11.4. SWOT Analysis
13.2.11.5. Strategic Overview

List of Table

Table 1: Overview of active clinical trials for scleroderma
Table 2: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 3: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 4: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 5: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 6: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 7: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 8: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 9: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024s
Table 10: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 12: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 13: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 15: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 16: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 18: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 19: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 20: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 21: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 22: North America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 23: Europe Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 24: Asia Pacific Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 25: Latin America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 26: Middle East & Africa Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024

List of Chart

Figure 1: Global Scleroderma Therapeutics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 2: Global Scleroderma Diagnostics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 3: Scleroderma Therapeutics Market Value Share by Drug Class (2016)
Figure 4: Scleroderma Therapeutics Market Value Share by Indication (2016)
Figure 5: Scleroderma Therapeutics Market Value Share by Region (2016)
Figure 6: Scleroderma Diagnostics Market Value Share by Test Type (2016)
Figure 7: Global Scleroderma Therapeutics Market Value Share Analysis, by Indication Type, 2016 and 2024
Figure 8: Global Localized Scleroderma Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 9: Global Systemic Scleroderma Market Revenue US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 10: Scleroderma Therapeutics Market Attractiveness Analysis, by Indication Type, 2015
Figure 11: Global Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 12: Global Corticosteroids Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 13: Global Immunosuppressive Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 14: Global Endothelin Receptor Agonists Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 15: Global Calcium Channel Blockers Market Revenue ((US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 16: Global PDE-5 Inhibitors Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 17: Global Chelating Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 18: Global Prostacyclin Analogs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 19: Global Other Scleroderma Drugs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 20: Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: Global Scleroderma Therapeutics Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015
Figure 23: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 24: North America Scleroderma Therapeutics Market Size and Y-o-Y Growth Projections, 2015–2024
Figure 25: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 26: North America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 27: North America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: highlights the estimated and forecast market value share of the drug class segments for 2016 and 2014
Figure 28: North America Scleroderma Therapeutics Market Value Share Analysis, by Country, 2016 and 2024
Figure 29: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 30: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 31: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 32: Europe Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 33: Europe Market Attractiveness Analysis, by Country, 2015
Figure 34: Europe Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 35: Europe Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 37: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 38: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 39: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Asia Pacific Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 41: Asia Pacific Market Attractiveness Analysis, by Country, 2015
Figure 42: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 43: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 44: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 45: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 46: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 47: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 48: Latin America Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 49: Latin America Market Attractiveness Analysis, by Country, 2015
Figure 50: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 51: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 52: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 53: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 54: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 55: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 56: Middle East & Africa Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 57: Middle East & Africa Market Attractiveness Analysis, by Country, 2015
Figure 58: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 59: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 60: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 61: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 62: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 63: Global Skin Biopsy Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024 
Figure 64: Global Imaging Techniques Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 65: Global Prostacyclin Analogues Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 66: Global Electrocardiogram & Echocardiogram Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 67: Global Pulmonary Function Tests Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024 
Figure 68: Global Scleroderma Diagnostics Market Attractiveness Analysis, by Test Type, 2015
Figure 69: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *